Cell therapies for cartilage repair and inflammatory disease, manufactured in-house under EU authorisation.
KELI develops and manufactures cell therapies in Kaunas, Lithuania. Six programmes in cartilage repair, inflammatory disease and fibrosis — one approved, one in a Phase 1b/2 trial.
- RECARTA — approved under Hospital Exemption, Lithuania; treatments from January 2027.
- KELI-101 — Phase 1b/2, CTA submission in progress.
- GMP site licence — application in progress.

€3.5M
EU and national grant funding awarded to KELI
Phase 1b/2
CTA submission in progress
1 authorised product
5 in development
2 international patent filings
PCT/EP and USPTO, 2026
2026-527099-98-00
EU clinical trial number
In-house ATMP manufacturing in Kaunas.

6
Programmes
Kaunas
Location
Chondrocytes
Platform
Placental MSC
Platform
Grade A–D
Cleanroom
Regulatory expertise in-house.
Two former members of EMA's Committee for Advanced Therapies (CAT) and CHMP lead KELI's regulatory and clinical strategy.
Meet the teamScience and partners.
22 peer-reviewed publications in cartilage repair and MSC research. Two international patent filings.
See the evidenceClinical partners in Lithuania and letters of intent from cardiac surgery and nephrology centres in Athens, Copenhagen, Essen and Leiden.
See partnersFor investors.
KELI is backed by €3.5M in EU and national grants, including a €2.5M EIC Accelerator grant, and is raising a seed round.
